Pelabresib,Ruxolitinib
morphosys
['morphosys']
$nasdaq [15s. delayed]: issued press release on june 10, 03:15:00: morphosys presents multiple analyses of the manifest phase 2 trial investigating the potential of pelabresib in the treatment of myelofibrosis at eha 2022 
Flash Alert is a low-latency financial news service which sources SEC, press releases, credible news sources to get your news about stocks in near real-time